BIOTEC - APPROVED PROSPECTUS AND SUBSCRIPTION PERIOD COMMENCES
Reference is made to the stock exchange notice published by Biotec
Pharmacon ASA (the "Company") 10 January regarding the completed private
placement of 9,500,000 New Shares (the "Private Placement") and the
contemplated subsequent offering of up to 2,500,000 Offer Shares (the
The Financial Supervisory Authority of Norway approved the following
prospectus 11 February 2013:
Listing of 9,500,000 New Shares resolved issued in connection with the
Private Placement of 9,500,000 shares completed on 10 January 2013 at a
subscription price of NOK 4.25, and listing of up to 2,500,000 Offer
Shares to be issued in the Subsequent Offering.
Subsequent Offering of up to 2,500,000 Offer Shares at a subscription
price of NOK 4.25 with pre-emptive rights for Biotec Pharmacon's
shareholders per 10 January 2013, with the exception of those
shareholders who were allocated New Shares in the Private Placement. The
Subsequent Offering comprises 2,500,000 subscription Rights, where each
subscription right grants the right to subscribe for one (1) Offer
Share. Each eligible shareholder will receive 0.1236 subscription rights
per share owned 10 January 2013. Oversubscription is allowed. The
subscription period is from 13 February 2013 to 27 February 2013 at
16:30 CET. Subscription rights not used to subscribe for Offer Shares
before the expiry of the subscription period will be of no value and
will automatically lapse without compensation to the holder.
Eligible shareholders will be notified in a separate letter. Please
refer to the Prospectus for further information.
The Subsequent Offering is managed by Carnegie AS. The Prospectus
together with the subscription form will be available at www.biotec.no
and www.carnegie.no, and will also be available free of charge at the
business offices of Biotec Pharmacon ASA and Carnegie AS. Norwegian
investors with a VPS account can in addition subscribe for Offer Shares
online at www.carnegie.no.
For further information please contact:
Chief Executive Officer
+47 92 28 93 23
+47 22 00 93 20
This information is subject of the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.